Astrana Health, Inc. Q1 FY2023 Earnings Call

Greetings. Welcome to Apollo Medical Holdings First Quarter 2023 Financial Results. Please note, this conference is being recorded. I will now turn the conference over to Carolyne Sohn, Vice President of Investor Relations. Thank you. You may begin.

Thank you, operator, and hello, everyone. Thank you for joining us. The press release announcing Apollo Medical Holdings, Inc.'s results for the first quarter ended March 31, 2023, is available at the Investors section of the company's website at www.apollomed.net. To provide some additional background on its results, the company has made a supplemental deck available on its website. A replay of this broadcast will also be made available at ApolloMed's website after the conclusion of this call. Before we get started, I would like to remind everyone that this conference call and any accompanying information discussed herein contains certain forward-looking statements within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terms such as anticipate, believe, expect, future plan, outlook and will and include, among other things, statements regarding the company's guidance for the year ending December 31, 2023, continued growth, ability to decrease cost of care while improving quality and outcomes, ability to deliver sustainable revenue and EBITDA growth as well as long-term value, ability to respond to the changing environment, ability to offset anticipated losses in the Care Enablement segment, ability to successfully implement operational streamlining and successful implementation of strategic growth plans, acquisition strategy and merger integration efforts. Although the company believes that the expectations reflected in its forward-looking statements are reasonable as of today, those statements are subject to risks and uncertainties that could cause the actual results to differ dramatically from those projected. There can be no assurance that those expectations will prove to be correct. Information about the risks associated with investing in ApolloMed is included in its filings with the Securities and Exchange Commission, which we encourage you to review before making an investment decision. The company does not assume any obligation to update any forward-looking statements as a result of new information, future events, changes in market conditions or otherwise, except as required by law. Regarding the disclaimer language, I would also like to refer you to Slide 2 of the conference call presentation for further information. For those of you following along with the accompanying supplement, there is an overview of the company on Slide 3. On today's call, the company's Co-Chief Executive Officer, Brandon Sim, will discuss first quarter 2023 highlights and the latest operational developments. Chief Financial Officer, Chan Basho, will follow with a review of ApolloMed's results for the first quarter ended March 31, 2023. Brandon will conclude the remarks with an update on the company's outlook and long-term growth strategy before opening the floor for questions. With that, I'll turn the call over to ApolloMed's Co-Chief Executive Officer, Brandon Sim. Please go ahead, Brandon.

Thank you, Carolyne, and good evening, everyone. Thank you for joining us today. We began 2023 with a strong first quarter as we continue to rapidly scale our leading value-based care enablement and delivery platform. While maintaining our long history of outstanding clinical outcomes and great healthcare experiences for our members and sustained profitability. I will first summarize our key quarterly financial results and reporting improvements, and then provide updates on operations. For the first quarter ended March 31, 2023, we reported total revenue of $337.2 million, a 28% increase from the prior year quarter, and $29.8 million in adjusted EBITDA. We are also introducing segment-based reporting, details of which are included on Slide 7 of our earnings supplement. As our business continues to grow, we felt it was important for us to provide greater clarity into each segment's revenue, growth, and operating profitability, which are the metrics by which we also evaluate our businesses, excluding non-operational factors. We believe this information will allow investors to better evaluate changes in the operating results of our business segments. Beginning with the first quarter ended March 31, 2023, we are reporting our financial results based on the following three business segments: Care Enablement, Care Partners, and Care Delivery. Our Care Enablement segment is an integrated end-to-end clinical administrative platform powered by our proprietary technology suite, which provides operational, clinical, financial, technology, management, and strategic services to providers and payers. Revenue for this segment is primarily comprised of management and software fees charged as a percentage of gross revenue or on a per member per month basis. Our Care Partners segment is focused on building and managing high-quality and high-performance provider networks by partnering with, empowering, and investing in strong provider partners with a shared vision for coordinated care delivery. By leveraging our unique Care Enablement platform and ability to recruit, empower, and incentivize physicians, we are able to organize partnered providers into successful risk-bearing organizations, which take on varying levels of risk based on total cost of care across membership in all lines of business, including Medicare, Medicaid, commercial, and exchange. Revenue for this segment is primarily comprised of capitation and risk full settlements and incentives. Finally, our Care Delivery segment seeks to provide high-quality and accessible healthcare services through a patient-centric care delivery organization. It consists of outpatient clinics providing primary care, multi-specialty care, including cardiology and women's health, urgent care, as well as ancillary services such as ambulatory surgical centers, diagnostic laboratory, and imaging services and hospitals. Revenue for this segment is primarily earned based on fee-for-service reimbursements, capitation, and performance-based incentives. Moving next to operations. We continue to execute on our operational goals of: one, growing our membership in core and new geographies; two, moving members along the risk ladder towards global risk value-based contracts; and three, enabling our providers to deliver excellent patient outcomes in order to manage that risk effectively. On the first goal, we've seen strong and steady progress. As Chan will detail later, we grew our Care Partners business by over 30% from the prior year quarter due to organic membership growth and a more favorable payer mix in our risk-bearing business. We also continue to make inroads in our newer Nevada and Texas geographies following our acquisition of Valley Oaks Medical Group last October. Since that time, we have increased unique members seen by 120%, and we're very excited about the ongoing growth in those regions, as we continue to provide excellent care to members of those communities. We believe that this growth will be sustainable for the years to come, as we execute on our second operational target of moving towards taking global risk on total cost of care for our patients. Last week, we closed on the acquisition of For Your Benefit or FYB along with receiving regulatory approval for the change in control of FYB's full-service Restricted Knox-Keene licensed health plan, which will allow us to take global risk for the professional and institutional cost of care for members in the plan. This is a significant opportunity for us to deploy our care coordination and management capabilities more effectively and enhances our demonstrated ability to decrease total cost of care while improving quality and patient outcomes. We expect that this will drive both revenue and EBITDA growth over the next several years. As guided to you in the past, we plan to assume additional risk in a prudent, measured fashion over the next several years, but we strongly believe that the infrastructure, technology, and operations we have developed position us strongly to succeed in this transition. Finally, on our third goal, we continue to see MLR trends to be favorable versus both prior periods and in line quarter-over-quarter. This is the result of improvements we've made in medical costs in our existing markets as well as new ones we've added over the past year. In addition to executing on our three stated goals above, we also strongly believe in investing in the care delivery ecosystem. While we have built what we believe to be a world-class platform for managing global risk in a multi-payer setting across all patient types, we also know that there are others building innovative and exciting solutions in the value-based care delivery ecosystem. To that end, in recent months, we have made small venture investments in areas we feel will enhance our ability to empower providers in the delivery of value-based care. We led the pre-seed funding for Third Way Health, a company looking to transform the front office for care delivery organizations. We also invested in two other companies: one focused on providing care to high-risk Medicare members and another focused on delivering technology-enabled services and infrastructure for value-based care providers and organizations. We're excited by the progress we have made so far in working with these innovators and look forward to continuing those partnerships. I also have two more operational updates to share. Recently, we were unable to come to mutually agreeable terms for the renewal of a management services contract with LaSalle Medical Associates, one of our clients in our care enablement business with approximately 370,000 members. That contract will thus terminate by the end of August of this year. In 2022, LaSalle contributed $21.4 million in net revenue on an annualized basis for the Care Enablement business. I want to emphasize that the impact of LaSalle only affects our Care Enablement segment and that its impact is under 2% of our total revenues for 2022. There will be no effect on our risk-bearing Care Partners segment. We expect to partially offset losses in revenue from this contract as we continually add new clients to our Care Enablement business. We are also taking this opportunity to streamline our operations and organizational structure, which have grown significantly over the past several years. While this was necessary to support the growth of the company, we currently have over 1,500 employees across our organization. We will be focusing on performance management, especially within our operating departments in order to ensure that the profitability and margins in our Care Enablement segment remain on track against our expectations. We are confident that we will be able to continue delivering high-quality healthcare experiences and driving positive outcomes for our members with a leaner operating structure that will position the company for greater success. Given the strength of our first quarter and despite the recent developments, we are reiterating our full year 2023 guidance on both the top and bottom line, which is listed in full on Slide 11 of our supplement. We aim to continue growing membership in our core California markets while scaling rapidly in our newer markets, making progress on moving patient cohorts towards global risk, and managing towards excellent clinical and financial outcomes. We are excited by our progress so far on these fronts and believe we are well positioned going forward into the rest of 2023. Before I turn it over to Chan, I wanted to congratulate him on his official appointment as Chief Financial Officer of ApolloMed effective last Friday. He will continue in his role as Chief Strategy Officer, and we're very pleased to have his leadership in the areas of finance, operations, strategy, and corporate development. Bringing his over 20 years of experience in these areas at various other healthcare companies, Chan has made invaluable contributions over the past year. And I'm thrilled to continue building with him in the years ahead. With that, I'll turn it over to Chan.

Thank you, Brandon. I want to thank you for the support and greatly value the opportunity. As we highlighted, we continue to deliver strong results, reporting total revenue of $337.2 million in the first quarter of 2023, a 28% increase from $263.3 million in the prior year quarter. This was primarily driven by increased revenue within our Care Partners segment. I'll quickly highlight our per-segment results and offer a brief commentary on each. First, our Care Enablement segment reported revenue of $30.6 million for the quarter, an increase of 4% from $29.4 million in the prior year period. Segment operating income decreased 49.3% to $5.7 million for the period, which was driven by our additional investments in infrastructure, technology, and people to support our operational growth. We believe that these investments are necessary, as we prepare to take on management services contracts related to global risk, and we expect margin expansion once fees for managing these global risk contracts begin to offset some of the investments made over the past year. Membership under management within our Care Enablement business segment was approximately 1.3 million managed lives at the end of the first quarter ended March 31, 2023. Approximately 650,000 or half of these members were also within our Care Partners business and have capitated risk-bearing arrangements through our consolidated risk-bearing entities. Deep diving into our Care Partners segment, revenue increased 30.4% to $314.7 million during the period, primarily driven by organic membership growth in our consolidated risk-bearing entities and a more favorable payer mix. Segment operating income increased 28.2% to $22.3 million, which was primarily driven by our ability to maintain a steady medical loss ratio and cost structure even with rising revenue. This is a result we're pleased with, and we will continue driving further growth in this segment by expanding our membership base and moving patients into global risk value-based arrangements. Finally, our Care Delivery segment revenue increased by 24.9% relative to the prior year period to $25.4 million. This was primarily driven by increased volume in patient visits to our primary multi-specialty and ancillary care delivery entities. The segment's operating loss was $1 million, relative to an operating income of $1.1 million in the prior year period. This was due to our continued investment in expanding our care delivery footprint in Nevada and Texas. We view the results in this segment as in line to better than the guidance we provided last quarter around investing an incremental $5 million to $10 million in 2023 to scale new geographies. Net income attributable to ApolloMed was $14.6 million, up 3% relative to $14.3 million in the first quarter of 2022. Earnings per share on a diluted basis were $0.31, which is flat compared to $0.31 in the prior year period, mainly due to increased operating expenses that I referenced earlier. We reported EBITDA of $24 million in the first quarter of 2023, up 1.2% from $23.7 million in the prior year period. Adjusted EBITDA for this period was $29.8 million. We placed greater emphasis on the adjusted EBITDA figure, as these numbers back out the impact of excluded assets, stock-based compensation, other income, and income from equity method investments. Turning over to the balance sheet, we remain well-capitalized and well-positioned to execute on our growth initiatives. We ended the first quarter with $274.6 million in cash and cash equivalents compared to $288 million at the end of 2022. Our working capital was $292.7 million, compared to $287.8 million at the end of 2022. Total stockholders' equity increased to $563.2 million at the end of March 31, 2023, from $555 million as of December 31, 2022. Total debt at the end of the first quarter was $205.6 million. Lastly, this past December, our Board authorized the repurchase of up to $50 million of the company's shares of common stock from time to time in the open market as well as privately negotiated transactions. The company repurchased $9.5 million or approximately 270,000 shares during the first quarter. As a note, this share repurchase plan has no expiration date. In summary, we remain confident in the long-term prospects of our business and operational strategy and are looking forward to the year ahead. I'd now like to turn it back to Brandon for a discussion of our growth strategy and outlook for the remainder of 2023.

Thanks, Chan. In closing, we have hit the ground running in 2023 and are very excited about our prospects for the remainder of the year. We are making notable progress on the key operational goals of organic growth in our core new markets, moving our risk-based membership towards global risk, and empowering a growing network of providers to deliver superior outcomes for their patients in order to effectively manage our increasing book of risk-based business. With that, operator, let's open it up for Q&A.

Operator Instructions. Our first question is from Ryan Daniels with William Blair.

I'd love to get a little bit more color on some of the G&A investments you're making and how we should think about that going forward, given some of the streamlining you mentioned. And in particular, would love to hear more about what you're doing in Care Enablement. I know that nearly doubled year-over-year, even though it's only about 10% of your sales. So maybe, one, talk about how we think about overall G&A going forward, and number two, specifically in Care Enablement?

This is Brandon. Thanks for joining the call. Good to hear from you. So around Care Enablement and overall G&A, I think there have been a lot of areas where we've invested in starting last year, and that's where you're seeing the same quarter year-over-year increases in G&A. With particular respect to Care Enablement, we've made a lot of investment in our analytics and software engineering departments, for example, which are leading to some of the increased G&A. We've also made investments into preparing for management services around institutional claims processing, authorization, case management, etc., which we've been doing in anticipation of one of our clients in the Care Enablement segment signing on for additional institutional-related services as well as our own Restricted Knox-Keene license going live this year. And so we'll start to see revenue come in to offset the increased G&A within the next quarter or two for the institutional investment. We do believe that G&A is going to slow down a bit for the rest of the year. Maybe Chan can talk a little bit about that.

Yes. Thanks, Brandon. Ryan, thanks for the question. So as we previously mentioned, the G&A increase that we saw last year really kicked in Q3 and Q4 is running at a steady state in Q1. And we expect '23 to be in line with full year 2022. And sorry about that, Ryan, in terms of the name.

No worries at all. And then maybe another big picture one, just on Medicaid redetermination. I know that's down to 20% of sales now, but any thoughts on the potential impact given your exposure to California Medicaid? I know you're payer agnostic, but certainly, some of those lives are going to lose coverage. So is that contemplated in guidance? And then how big of an impact could that have?

Yes. We're just starting to see redetermination kick in in May, and those numbers are built into our guidance. Give us about till next quarter to give you exactly the movement that we're seeing from Medicaid over to the exchange with the robust policies that are in place in California. We do expect to capture many of those members as the process happens.

Okay. Perfect. And then maybe last one, just any more color, I'm sure we'll get some questions on LaSalle Medical Group and the Care Enablement agreement there with the MSA being discontinued as of August. Was it a pricing issue? Was it anything with dissatisfaction with the technology, just normal business? And then maybe you can remind us what the typical length of contract terms are in your historic retention rates?

Sure thing, Ryan. I can take this one. Around the MSO, our Care Enablement clients are important to us. We really do our best not to lose any, and this is actually a pretty rare occurrence for us. I think our retention rate is well in the 90s, and net retention from a revenue basis is probably over 100 to answer your other question. But I think in this particular instance, in those numbers I cited earlier, obviously, excluding LaSalle just to date, and that contract ends August 31 of this year. Unfortunately, with LaSalle, we were unable to come to terms with pricing that supported the long-term margins that we wanted in business, which are 20% to 30%. And there's a bit of a difference in kind of strategy that I probably won't go too deep into on this call, but unfortunately, these things happen. What I can say is that going forward, we do anticipate to build to ensure that the Care Enablement segment is still on track towards the 20% to 30% EBITDA margins that we've talked about. And there is a pipeline of folks who are excited to get back on board or to get on board, sorry, in the Care Enablement segment.

Our next question is from Brooks O'Neil with Lake Street Capital Markets.

Good afternoon, guys, and congratulations on the strong start to the year. Congratulations to Chan. I think it's fantastic. I look forward to continuing to work with you guys. So I have a couple of questions. I guess I'd like to start off, obviously, when you comment about trimming up the workforce, I've heard some other rumblings around from some other health plan organizations that they're considering staffing reductions. Would you say that in response to reimbursement level in any parts of your business in particular, Ryan mentioned, the redetermination in Medicaid. But I've heard that there's some pressures in the Medicare Advantage business broadly defining, can you comment if you guys are seeing that or feeling that?

Sure. Yes. Brooks, thanks for joining. Good to hear from you. I can certainly comment on that. I think around Medicare, we haven't seen as much pressure as perhaps the organization — or perhaps the industry on average has seen. I think some of those pressures that folks are anticipating are related to the RADV changes that will be phased in over the next three years, some risk adjustment changes from CMS. I think as we've stated before and continue to believe the risk adjustment changes will not affect us as much as other organizations. We've run some analysis around the prevalence of certain codes or combinations of codes that will be eliminated or reduced in terms of risk adjustment contributions. And it's just not as high as we think. That combined with the rate of growth for us and the heightened base demographic score for risk adjustment should end up being a bit of a wash. So I think we're feeling okay on the Medicare side of things. The main realignment or streamlining, so to speak, for the organization will really be, we grew very quickly. We grew at over 1,500 employees currently. We're talking about cuts of 5% or less. To be honest, it's not a large thing, but it is something we have to do to ensure that our margins in the Care Enablement business are going to be robust and on track for the 20% to 30% long-term margins that we've guided towards in the past. So that's really the scope and the rationale for the streamlining.

So second question I have or I guess, to make a quick comment that I'm wildly excited about your opportunity with the Restricted Knox-Keene license. I was hoping you might tell us a little bit about how you expect to take advantage of that. Obviously, the San Francisco market is one opportunity, but since it applies in the whole state, it seems like just an enormous opportunity for you. And maybe you could share with us how you envision the financial effect of that and how you expect to take advantage over the next couple of years?

Sure. Yes. Thanks for the question, Brooks. So we received regulatory approval from the state for the Restricted Knox-Keene license health plan. As we mentioned, currently for two counties, so it's a fairly small group of members today, around 5,000 senior members, for whom we're taking global risk via the Restricted Knox-Keene license. Chan and I are working hard to ensure that this is operationalized across other counties in California, including ones in which we have the bulk of our risk-bearing Care Partners membership. And so you'll start seeing results of that show up in the Care Partners segment as we do that. Chan, do you want to talk a little more in depth about the impact on the bottom line?

Sure. Brooks, thanks so much for the kind words. Great to hear from you. Yes. Short term, in terms of top line, we have about under 10,000 members that will initially be within FYB, and we're working to quickly expand it from the San Francisco Bay area to other locales within California. In terms of bottom line, I would say for the initial 12 months, it's going to be breakeven. We expect over time, the revenue will come in line with our overall long-term margins that we've guided to historically.

Great. Could I just ask one more follow-up on that? Obviously, FYB had some experience managing global capitation, global risk. Would you say your organization, more broadly, has significant experience with that? Or is that going to be a learning curve for the organization going forward?

Yes. We've been managing institutional risk via our dual risk arrangements — full risk arrangements, as called California, for some time, even in Southern California, a fairly large book of business. We've also hired most, if not all, of the FYB related staff, which contributed partially to the increased G&A in the Care Enablement segment because the revenues haven't come in yet, but we've already hired the staff. And so that's kind of a bit of what I was alluding to earlier with some of the fees related to institutional revenue coming in to offset the increased G&A that we had to invest in. And there's a bit of a quarter timing issue there. So we expect those margins to kind of climb back up in line in the Care Enablement segment. On the Care Partners segment, where the actual risk will be borne, as Chan mentioned earlier, we think we can get a 10% to 20% long-term margins even on the close to doubled revenue in that segment. So to answer your question, yes, we're confident in our ability to do it. We've hired the folks and made the investments we need to. What's left is really operationalizing the contract across California.

Let me just ask one more; appreciate all the color. Can you just give us an update on what's going on, if anything, with regard to sort of the traditional Medicare programs you've been involved in? In the past, you've performed incredibly well. I'm just curious what you envision either this year or next year in those areas?

Brooks, so last year, we were in the DCE program for our — and that has now transitioned to the ACO REACH program. As we think about our 2022 performance, we really viewed this as a breakeven business. In 2023, we continue to evaluate. As we get further data, especially around the retrospective trend adjustment factor, which is a benchmark used by CMS regarding historical revenues versus current revenues, we'll be able to provide more insight probably by Q3.

Operator Instructions. Our next question is from Adam Ron with Bank of America.

I have a couple of questions. So I guess following around the ACO REACH, are you saying last year was breakeven in this year? You're accruing for basically 100% MLR in the program? And if so, if that's how things end up playing out, like is that a program still worth being in? Like it adds scale and revenue and kind of breakeven introduces new provider relationships? Or is it not really playing out versus what expectations were? And then would you seek out like an MSSP or what is the general thought process around that?

Yes. I mean, long term, we would want to be in a business where we are able to achieve margins similar to other books of business. And you are right in your earlier statements, Adam, that for 2022 was breakeven, and we are accruing in terms of 2023. That's where we're starting. I think we are being very conservative, and we're still learning about the program. We've had many fluctuations in the retrospective adjustment factor so it's hard to get to move in any other way. As we approach May, we will receive our summary for 2022, and then the final reconciliation happens in August. We'll be able to provide a lot more insight on '22 there. In terms of '23, as we start seeing that retrospective trend adjustment factor stabilize, we can also provide more insight. As for your third question around other programs, we're definitely evaluating other programs in terms of our long-term focus on providing a full range of offerings and services for all members.

All right. Appreciate that. And then going back to another question about the Knox-Keene conversion. If you could add some additional color around the potential timing of converting it across your other capitated lives in California. Like what is it tied to? Is it tied to provider-payor contracts and so those expire over the course of two to three years? And if that's the case, like what is the lumpiness associated with that? And then second, I didn't fully understand how the EBITDA conversion on that would work? Like would it be symmetrical if you're going from like 40% risk to 100% risk if EBITDA should convert that way? Or was your hospital partner already sharing through the risk pool incentives, some of what the upside would be of taking full risk and so it's somewhere in between 40% and 100%?

Adam, this is Brandon. Thank you for joining the call. Good to hear from you. I can take this one. So around the timing of the operationalization of the RKK license, you're right; there will be lumpiness to it because it depends on the specific health plan partner and county combination to sign and then approve and move into the global risk arrangements. We don't necessarily have to wait until the expiration of each contract. So it's not like we have to wait two to three years. That's something we're negotiating on a plan-by-plan basis to ensure it gets done as soon as possible. I would guide at least one plan in Southern California. We expect to be within the Restricted Knox-Keene umbrella this year in 2023 and the rest should be phased in over the next 18 to 24 months. The delay really is around contracting with each payer and we're very diversified in our payer mix and contracting with the appropriate hospital systems based on the adequacy. So that's something we've been working on already. Some of the investments we've been making on the Care Enablement side. And like I said earlier, we should have some results to show sometime this year. In terms of conversion to EBITDA of the increased revenue — the risk revenue related to those moving into global risk, we're conservatively saying that we should expect only a couple of percent of that to convert to EBITDA year zero because we're going to try to maintain the existing hospital relationships that keep in pull from a financial perspective. Over time, we expect that EBITDA to accrue such that in the long term, it's 10% to 20% EBITDA margin.

And you made an interesting comment about the new geography investments coming in better than you expect. So less dilutive than the $5 million to $10 million you initially guided to. What specifically is driving that? Is it like you're growing patients faster, and so there's more fixed cost coverage or MLR ramping better? And based on what you're seeing, I guess, is there anything to call out? Or do you see opportunity to invest further? Or what metrics are you seeing? And what do you need to see to expand further into next year in these new markets?

Yes, totally. So in Q1, you can see in our Care Delivery segment, which is where most of the investments we're making in new geographies came in around $2 million less in terms of operating income relative to last year's Q1. And that's kind of the extent of the investments we've been making. So it's around $8 million on an annualized run rate basis. I think we guided towards 5% to 10% in each of the new markets. So it's on track to slightly lower in terms of an operating income hit than guided towards. The progress has been good. We've been adding a lot of the investments include adding net new providers, for example, and it takes time to ramp those providers up in terms of their patient panels. We're moving the fee-for-service folks into partial risk arrangements over time as well. So there's some investment needed for the infrastructure on the ground to operationalize that. So I would say it's going better than expected. Membership, as I mentioned earlier in the prepared remarks, has been growing ahead of the curve. We're monitoring a number of fee-for-service members, the number of capitated members, Star scores, incentive reimbursements and so on, and things are tracking. So really, it's going to be a small "J curve" as we add on new providers to ramp for our patients, but we expect it to be kind of in the 10,000 Medicare mark sooner than expected.

Okay. Great. And then I guess my last question is broader. Basically, we covered a lot of the managed care companies, and it seems like the trend broadly has been more controlled or tighter than maybe some expected possible companies and med tech companies are talking about accelerating volumes. And so just curious what you're seeing in terms of your capitated risk business around trend and what you're assuming for the rest of the year, and how things came in versus expectations?

Yes. You can see our Care Partners business operating income actually grew quite well in line with revenue growth. So if I'm — please correct me if I'm misunderstanding your question, but we're seeing volumes moderate, and we're keeping our medical loss ratios in control. You mentioned it's favorable relative to Q1 last year, and approximately in line, I think it was like a 30 basis point increase from Q4 of last year to this year, but let me know if I missed your question.

Yes. No, I guess things came in better than expected. I'm just curious, like into April, if things are continuing as you accrued and built into guidance?

Yes, we're seeing margins in line with Q1 going into Q2, yes. I wouldn't say it's materially better. It's probably in line.

We have reached the end of our question-and-answer session. I would like to turn the call back over to Brandon for closing comments.

Great. Well, thank you all for your time today. We appreciate it. We thank you for joining the call. We're always open to a dialogue with investors and welcome visitors to our offices in Los Angeles. Please feel free to reach out to us or our Investor Relations firm if you have any additional questions. We look forward to speaking to you all again on our next quarterly call. Thank you.

Thank you. This will conclude today's conference. You may disconnect your lines at this time, and thank you for your participation.